Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Regenerative Stem Cell Therapy Optimization via Tissue Engineering in Heart Failure with Reduced Ejection Fraction

Regenerative Stem Cell Therapy Optimization via Tissue Engineering in Heart Failure with Reduced... The prevalence of heart failure (HF) is continuously rising in both the industrialized and non-industrialized nations. Despite current therapeutic advances, prognosis of HF patients remains poor. Presently, therapeutic pharmacological and device strategies for HF with reduced ejection fraction (HFrEF) are mostly palliative and do not induce regeneration of lost myocardial tissue. Stem cell therapy has demonstrated promising results in clinical studies by promoting myocardial restoration in HFrEF subjects. Despite decades of investigation, many challenges remain unanswered to the widespread clinical application of stem cell therapy for HFrEF. This review will describe the foundational work already accomplished in cardiac stem cell therapy, advantages and limitations of the various candidates for tissue restoration, their presumed mechanisms of action, the role of scaffolding materials as well as the challenges that exist for widespread clinical application. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiovascular Engineering and Technology Springer Journals

Regenerative Stem Cell Therapy Optimization via Tissue Engineering in Heart Failure with Reduced Ejection Fraction

Loading next page...
 
/lp/springer_journal/regenerative-stem-cell-therapy-optimization-via-tissue-engineering-in-XIucbGfq5P

References (65)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Biomedical Engineering Society
Subject
Engineering; Biomedical Engineering; Cardiology; Biomedicine, general
ISSN
1869-408X
eISSN
1869-4098
DOI
10.1007/s13239-017-0325-y
pmid
28849552
Publisher site
See Article on Publisher Site

Abstract

The prevalence of heart failure (HF) is continuously rising in both the industrialized and non-industrialized nations. Despite current therapeutic advances, prognosis of HF patients remains poor. Presently, therapeutic pharmacological and device strategies for HF with reduced ejection fraction (HFrEF) are mostly palliative and do not induce regeneration of lost myocardial tissue. Stem cell therapy has demonstrated promising results in clinical studies by promoting myocardial restoration in HFrEF subjects. Despite decades of investigation, many challenges remain unanswered to the widespread clinical application of stem cell therapy for HFrEF. This review will describe the foundational work already accomplished in cardiac stem cell therapy, advantages and limitations of the various candidates for tissue restoration, their presumed mechanisms of action, the role of scaffolding materials as well as the challenges that exist for widespread clinical application.

Journal

Cardiovascular Engineering and TechnologySpringer Journals

Published: Aug 28, 2017

There are no references for this article.